News >

Better Patient Selection Needed for AML Therapies

Chelsea LoCascio
Published: Thursday, Nov 30, 2017

Alexander E Perl, MD

Alexander E Perl, MD
While there are many remaining therapeutic challenges for patients with acute myeloid leukemia (AML), recent advances with drug approvals and an improved understanding of how to treat patients with the disease are steps in the right direction, according to Alexander E. Perl, MD.

on Hematologic Malignancies, Perl, an associate professor of medicine at Perelman School of Medicine at the University of Pennsylvania, discussed the future of FLT3 inhibitors, current obstacles with treating patients with AML, and what pivotal trial results the community can expect to hear in the coming months.

OncLive: What did you discuss in your presentation?

Perl: We are getting better at defining which patients respond to which therapies in terms of targeted therapies—which is not a new idea, but a new option in the clinic. We have never had that before like we have now. Even with certain subsets, whether they are patients who respond to CPX-351 (Vyxeos), which is a different formulation of older chemotherapy, this seems to work better than the traditional way that we treated AML. That's an exciting advance, as well.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication